Expanding access to care beyond the hospital.
Featured Research
A New Standard for Pancreatitis Care
A landmark study published in the Journal of Veterinary Internal Medicine (JVIM) [https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.70217] proves that the RxActuator Mini-Infuser™ enables a highly successful outpatient protocol for managing canine pancreatitis.
By delivering continuous, low-dose subcutaneous analgesia, the device maintains a steady-state therapeutic level that allows stable patients to recover in the comfort of home rather than a high-stress ICU. This shift from prolonged hospitalization to evidence-based outpatient care ensures gold-standard pain management while significantly optimizing clinic resources.
Clinical Outcomes & Efficacy
89.5% Outpatient Success: 17 of 19 dogs were successfully managed as outpatients, avoiding the need for multi-day inpatient stays.
Complete Pain Resolution: Median pain scores (GCMPS) plummeted from a 7.5 to 0 within the first 48 hours of treatment.
Rapid Symptom Reduction: Patients saw a 50% decrease in clinical severity scores (MCAI) during the 48-hour infusion period.
Zero "Peak & Valley" Risk: Constant-rate infusion (CRI) maintains consistent drug levels, eliminating the toxic spikes and sub-therapeutic dips common with bolus dosing.
Financial & Operational Impact
Maximize Cage Throughput: Transitioning stable patients home on Day 1 frees up critical ICU space for higher-margin surgical or emergency cases.
Reduced Technician Labor: The silent, water-activated pump eliminates "nuisance alarms" and the need for constant IV line monitoring, allowing staff to focus on high-priority tasks.
Increased Client Compliance: By reducing the cost barrier of traditional $3,000+ hospitalization, more pet owners can opt for advanced treatment, improving overall practice revenue.
Optimized Practice ROI: Recapture "Device + Oversight" revenue while eliminating the low-margin overhead of long-term boarding and maintenance.
"Outpatient management of suspected pancreatitis cases can be safe."
Practice ROI & Capacity Multiplier Calculator
Earlier Discharging utilizing RxActuator's Mini-Infuser
Based on JVIM Outpatient Pancreatitis Protocols (Erger & Cridge et al. 2025)
Monthly Revenue Boost
$7,400
By transitioning Day 2-4 care home, you unlock surgical capacity and capture device revenue.
New Annual Profit: $88,800
*Calculation includes a $450 combined markup and oversight fee per Mini-Infuser™ protocol.
Why
the
math
works
1. Capture the Revenue, Lose the Overhead
Traditional hospitalization is labor-intensive. When you discharge a pancreatitis patient with the Mini-Infuser™, you keep the high-margin "Protocol and Device" revenue without the "low-margin" overhead of cage cleaning, overnight monitoring, and technician fatigue.
2. The Surgery Backfill
Every pancreatitis patient taking up a cage for 5 days is a patient that could have been a TPLO, a Gastrotomy, or an Acute Emergency. By leveraging the 89.5% success rate of the Erger & Cridge protocol, you turn your hospital into a high-throughput center of excellence.
3. Technician Retention
Nuisance alarms on infusion pumps and managing "tethered" dogs are leading causes of technician burnout. RxActuator's silent, water-activated technology removes the noise and the labor, allowing your team to focus on high-skill tasks.
Dosing Tables by Weight
| Ketamine at 3 micrograms/kg/minute | See Table |
| Ketamine at 4 micrograms/kg/minute | See Table |
| Hydromorphone at 0.01 mg/kg/hr | See Table |
Chronic Pain and Ketamine
Maximize your clinic's impact on canine chronic pain with the Mini-Infuser drug delivery pump, providing precise ketamine infusions that target NMDA receptors to reverse central sensitization. This advanced system offers a transformative, multimodal solution for treating maladaptive pain and improving long-term quality of life for veterinary patients.
| Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP | A Novel Approach with a Familiar Tool—Part 1 Review of Ketamine and Chronic Pain | Read Paper |
| Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP | A Novel Approach with a Familiar Tool—Part 2 Clinical Application and Case Studies | Read Paper |
| Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP | Ketamine and Maladaptive Pain | Watch Video |
Acute Pain and Hydromorphone
The RxActuator Mini-Infuser® provides a solution for outpatient canine pain management by delivering a consistent 48-hour subcutaneous infusion of hydromorphone at therapeutic plasma levels. This wearable drug delivery pump ensures reliable, long-term analgesia for dogs, overcoming the limitations of traditional bolus dosing for chronic and moderate pain.
| James S. Gaynor, DVM, MS, DACVAA, DAIPM | The Perfect Pump: Wearable Pumps for Pain Control | Read Paper |
| K. Messenger ; H. Enomoto ; H. Knych ; M. Papich | Pharmacokinetics of Hydromorphone in Dogs after Intravenous Bolus and Delivered Subcutaneously with the RxActuator Mini-Infuser® Infusion Pump | Read Paper |
| Kristen Messenger, Hiroko Enomoto, Melanie Madsen, Heather Knych, and Mark Papich |
Pharmacokinetics of Hydromorphone in Dogs after Intravenous Bolus and Delivered Subcutaneously with the RxActuator Mini-Infuser® Infusion pump |
View Presentation |
Anti Microbial Infusion with Ceftazidime
The RxActuator Mini-Infuser® ensures optimal therapeutic outcomes for time-dependent antimicrobials by delivering a continuous 48-hour subcutaneous infusion of ceftazidime in dogs, eliminating frequent, stressful injections while maintaining steady-state plasma concentrations essential for treating resistant canine bacterial infections.
| Mark G. Papich DVM, MS, DACVCP Melanie Madsen DVM Kristen Messenger DVM, PhD, DACVAA, DACVCP Hiroko Enomoto DVM | Ceftazidime pharmacokinetics in dogs after intravenous injection and delivered with the RxActuator Mini-Infuser infusion pump | Read Paper |